Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

FDA Grants Vertex Kidney Disease Drug Breakthrough Therapy Designation

The FDA granted breakthrough therapy designation to a Vertex Pharmaceuticals kidney disease drug.
Zacks Investment Research on MSN

Vertex (VRTX) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Zacks Investment Research on MSN

Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $381.87, demonstrating a +1.39% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 0.5%. At ...
Business News Daily

How Businesses Are Collecting Data (And What They’re Doing With It)

This guide was reviewed by a Business News Daily editor to ensure it provides comprehensive and accurate information to aid your buying decision. As technologies that capture and analyze data ...